Glucokinase activators hold the promise of profound efficacy in controlling both postmeal and fasted blood glucose in patients with Type 2 diabetes. They have the potential to be highly effective ...

That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904. Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical ...